Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

Investigational new drugs·2026
Same author

Analysis of Clinical Benefit Using DNG64-<i>CAR-V</i> Chimeric Tumor Targeted Amphotropic RNA Vector in <i>CCNG1</i> Expressing Cancers.

Anticancer research·2026
Same author

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.

Future oncology (London, England)·2025
Same author

Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients.

Cancer research communications·2025
Same author

Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Related Experiment Video

Updated: Mar 20, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.

Erlinda M Gordon1, K Kumar Sankhala2, Neal Chawla2

  • 1Sarcoma Oncology Center/Cancer Center of Southern California, Santa Monica, CA, 90403, USA. egordon@sarcomaoncology.com.

Advances in Therapy
|May 29, 2016
PubMed
Summary

Trabectedin, a marine-derived alkaloid, shows improved progression-free survival in patients with advanced liposarcoma or leiomyosarcoma. This chemotherapy offers a new option for patients who have not responded to prior treatments.

Keywords:
Alkylating agentChemotherapyClinical trialsDNA minor groove binderET-743OncologySoft tissue sarcomaTrabectedin

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.7K

Related Experiment Videos

Last Updated: Mar 20, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.7K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Trabectedin (ET743) is a marine-derived natural alkaloid with complex mechanisms of action.
  • It has undergone extensive clinical evaluation for various solid malignancies.

Purpose of the Study:

  • To review the USFDA approval of trabectedin for specific soft tissue sarcomas.
  • To summarize its efficacy, safety, and potential future applications.

Main Methods:

  • Review of pivotal Phase 3 trial data comparing trabectedin to dacarbazine.
  • Analysis of adverse events and outcomes from Phase 2 trials.

Main Results:

  • Trabectedin demonstrated a significant improvement in progression-free survival versus dacarbazine in liposarcoma and leiomyosarcoma.
  • Common adverse events included nausea and fatigue; serious events involved neutropenic sepsis and hepatotoxicity.

Conclusions:

  • Trabectedin is approved for unresectable or metastatic liposarcoma/leiomyosarcoma after anthracycline failure.
  • It shows potential as a first-line agent and in combination therapies for various sarcomas.